Frontiers in Medicine (Dec 2022)

Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: A cluster analysis

  • Varsha Parthasarathy,
  • Karen Cravero,
  • Junwen Deng,
  • Zhe Sun,
  • Sarah M. Engle,
  • Autum N. Auxier,
  • Nathan Hahn,
  • Jonathan T. Sims,
  • Angela J. Okragly,
  • Martin P. Alphonse,
  • Shawn G. Kwatra

DOI
https://doi.org/10.3389/fmed.2022.1011142
Journal volume & issue
Vol. 9

Abstract

Read online

ImportancePrurigo nodularis (PN) is a chronic heterogeneous inflammatory skin disease.ObjectiveTo elucidate which components of type 2 inflammation are dysregulated systemically in PN.DesignWhole blood was obtained from PN patients with uncontrolled disease and control patients without pruritus. Plasma was assayed for IL-4, IL-5, IL-13, IgE, and periostin. ANOVA was utilized to compare PN and control patients and multiple-hypothesis adjusted p-value was calculated with the significance threshold at 0.05. Clustering was performed using K-means clustering.ParticipantsPN patients (n = 29) and controls (n = 18) from Johns Hopkins Dermatology had similar age sex, and race distributions.ResultsSingle-plex assays of the biomarkers demonstrated elevated circulating plasma IL-13 (0.13 vs. 0.006 pg/mL, p = 0.0008) and periostin (80.3 vs. 60.2 ng/mL, p = 0.012) in PN compared to controls. IL-4 (0.11 vs. 0.02 pg/mL, p = 0.30) and IL-5 (0.75 vs. 0.40 pg/mL, p = 0.10) were not significantly elevated, while IgE approached significance (1202.0 vs. 432.7 ng/mL, p = 0.08). Clustering of PN and control patients together revealed two clusters. Cluster 1 (n = 36) consisted of 18 PN patients and 18 controls. Cluster 2 (n = 11) consisted entirely of PN patients (p < 0.01). Cluster 2 had higher levels of IL-13 (0.33 vs. 0.008 pg/mL, p = 0.0001) and IL-5 (1.22 vs. 0.43 pg/mL, p = 0.03) compared to cluster 1.Conclusion and relevanceThis study demonstrates elevation of IL-13 and periostin in the blood of PN patients, with distinct clusters with varying degrees of type 2 inflammation. Given this heterogeneity, future precision medicine approaches should be explored in the management of PN.

Keywords